| Cat.No. | Name | Information |
|---|---|---|
| M13528 | AZD-5991 | AZD-5991 is a potent and selective Mcl-1 inhibitor with an IC50 of 0.7 nM in FRET assay and a Kd of 0.17 nM in surface plasmon resonance (SPR) assay. |
| M13526 | A-1155463 | A-1155463 is a highly potent and selective BCL-XL inhibitor with an EC50 of 70 nM in Molt-4 cell. |
| M5273 | S63845 | S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor; binds human MCL1 with a Kd of 0.19 nM. |
| M2017 | ABT-199 (Venetoclax) | ABT-199 is a highly potent, orally bioavailable and BCL-2 inhibitor. ABT-199 is the first inhibitor targeting Bcl-2 and PPI. |
| M1637 | ABT-263 | ABT-263 (Navitoclax) is a potent, orally bioavailable inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-x (L), and Bcl-w. |
| M29950 | BT2 | BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC). BT2 is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM. |
| M22479 | Lisaftoclax | Lisaftoclax (APG-2575) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. |
| M21643 | VU661013 | VU661013 is a novel, potent, selective MCL1 inhibitor with Ki of 97 ± 30 pM to human MCL-1 in a TR-FRET assay. VU661013 destabilizes BIM/MCL1 association, leads to apoptosis in AML, and is active in venetoclax-resistant cells and xenografts. |
| M21156 | BI-3802 | BI-3802 is a potent degradation of oncogenic transcription factor BCL6 with strong inhibitory effect on target genes and anti-proliferative effect.BI-3802 inhibits the BTB structural domain of BCL6, corresponding to an IC50 value ≤ 3 nM.BI-3802 has anti-tumor activity. |
| M20819 | Obatoclax (GX15-070) | Obatoclax (GX15-070) is an antagonist of Bcl-2 with an Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. |
| M13529 | BAI1 | BAI1 is a selective and allosteric inhibitor of BAX, an apoptosis regulator. BAI1 directly binds to BAX and allosterically inhibits BAX activation. BAI1 has the potential for the research of diseases mediated by BAX-dependent cell death. |
| M13527 | (R)-(-)-Gossypol acetic acid | (R)-(-)-Gossypol acetic acid (AT-101 (acetic acid)) is the levorotatory isomer of a natural product Gossypol. |
| M13381 | Pyridoclax | Pyridoclax is a potential McL-1 inhibitor. |
| M13380 | Tapotoclax | Tapotoclax is an inhibitor of myeloid leukemia cell differentiation protein McL-1 (myeloid leukemia-1) with a Ki value of 0.13 nM and has potential pro-apoptotic and anti-tumor activity. |
| M10283 | AZD-5991 Racemate | AZD-5991 Racemate is a Mcl-1 inhibitor with an IC50 of <3 nM in FRET assay. |
| M9419 | Bax inhibitor peptide V5 | Bax inhibitor peptide V5 is a Bax-mediated apoptosis inhibitor. |
| M9248 | CID5721353 | CID5721353 is a B-Cell Lymphoma 6 inhibitor with IC50 of 212 μM. |
| M9095 | Marinopyrrole A | Marinopyrrole A (Maritoclax) is a novel and specific Mcl-1 inhibitor with an IC50 value of 10.1 μM. |
| M9044 | MIK665 | MIK665 is an inhibitor of induced myeloid leukemia cell differentiation protein (Mcl-1; Bcl2-L-3). |
| M8920 | BDA-366 | BDA-366 is a small molecule antagonist that specifically binds the BCL2 BH4 domain, and has the ability to convert anti-apoptotic BCL2 into a pro-apoptotic death molecule. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
